Back to results
US 7,119,122 B2Granted
Compounds for the inhibition of nitric oxide synthase
AssigneeAstraZeneca AB
InventorsStephen Connolly, Glen Ernst
Life of this patent
Estimating the term…
Abstract
There are provided novel compounds of formula (I) wherein A, R1, R3, R4, R5, T, U, V, W, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory diseases, pain and CNS diseases
Claims12
A compound of formula (I)
- wherein:
- A represents a phenyl ring or A represents a C8 to 10 aromatic or partially aromatic bicyclic ring system;
- R1 represents C1 to 6 alkyl, C1 to 6 alkoxy, halogen, hydroxy, cyano, trifluoromethyl or NR6R7;
- R3 represents hydrogen, C1 to 6 alkyl, C2 to 6 alkenyl, C3 to 6 cycloalkyl, C1 to 6 alkylthio, C1 to 6 alkoxy, halogen, hydroxy, cyano, trifluoromethyl or NR8R9;
- said alkoxy group being optionally further substituted by hydroxy or by one or more fluorine atoms;
- or R3 represents phenyl or a five- or six-membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N;
- said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, hydroxy, cyano or NR8R9;
- said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;
- R4 and R5 independently represent hydrogen or C1 to 6 alkyl;
- said alkyl group being optionally substituted by OH, C1 to 6 alkoxy, NR10R11 or phenyl;
- said phenyl group being optionally further substituted by C1 to 6 alkyl, C1 to 6 alkoxy, halogen, hydroxy, cyano or NR12R13;
- R6, R7, R8, R9, R10, R11, R12 and R13 independently represent hydrogen or C1 to 6 alkyl;
- said alkyl group being optionally substituted by OH or C1 to 6 alkoxy;
- or the groups NR4R5, NR6R7 and NR8R9 independently represent a 4- to 7-membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O or N;
- said ring being optionally substituted by OH, C1 to 3 hydroxyalkyl or C1 to 3 alkoxy;
- V represents cyano or nitro;
- X represents O or S(O)n;
- n represents an integer 0, 1 or 2;
- Y represents C1 to 6 alkyl;
- each of T, U and W represents CR2;
- and each R2 group independently represents hydrogen, C1 to 3 alkyl, C1 to 3 alkoxy or halogen;
- or a pharmaceutically acceptable salt thereof;
- with the provisos 1) that when A represents phenyl, V represents nitro, Y represents CH2, X represents S, and the group Y—NR4R5 is bonded to the phenyl ring ortho to X, then R4 and R5 do not both represent CH3, 2) that when V represents CN, X represents S, Y represents C1 alkyl, R3 represents H, and R4 and R5 both represent C1 alkyl, then R1 cannot represent a C1 alkyl, and 3) that when R1 represents Cl, V represents NO2, X represents O, and R3, R4 and R5 represent H, then Y cannot represent a C2 alkyl.
20 more elements
Dependencies are inferred from the claim text.